Levodopa (L-DOPA, L-dopa), CAS No. 59-92-7 high purity 20% content compliant with EP and USP grade standards LYNA Bio
TDS 7 Inquiries
59-92-7
Pharmaceutical Grade
99%
Shanghai
LYNA
1g/vial
2026-10-10
Urolithiasis B/Spermine Hydrochloride/ Apigenin/ Theacrine/FAA/OEA/PEA Theobromine/ Squid Ink Powder
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceL-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease. L-DOPA is the precursor of dopamine and product of tyrosine hydroxylase.Target: Dopamine ReceptorL-DOPA (L-3,4-dihydroxyphenylalanine) is a chemical that is made and used as part of the normal biology of humans, some animals and plants. Some animals and humans make it via biosynthesis from the amino acid L-tyrosine. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and
Solid
L-dopa is an optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease It has a role as a prodrug, a hapten, a neurotoxin, an antiparkinson drug, a dopaminergic agent, an antidyskinesia agent, an allelochemical, a plant growth retardant, a human metabolite, a mouse metabolite and a plant metabolite. It is a dopa, a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-dopa(1-). It is an enantiomer of a D-dopa. It is a tautomer of a L-dopa zwitterion.|Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975.|Levodopa is an Aromatic Amino Acid.|Levodopa (L-Dopa) is an amino acid precursor of dopamine and is the most effective and commonly used drug in the treatment of Parkinson disease. Levodopa is usually combined with carbidopa, which is an inhibitor of L-amino acid decarboxylase, the plasma enzyme that metabolizes levodopa peripherally. Treatment with the combination of levodopa and carbidopa has been associated with mild and transient increases in serum enzymes in a proportion of patients and with very rare instances of clinically apparent acute liver injury.|Levodopa is an amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS.|The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.CertificatesBasic Info-
Product Name:
DOPA
Other Name:L-Tyrosine,3-hydroxy-;Alanine,3-(3,4-dihydroxyphenyl)-,L-;3-Hydroxy-L-tyrosine;DA;(-)-3,4-Dihydroxyphenylalanine;Levodopa;L-3,4-Dihydroxyphenylalanine;3,4-Dihydroxy-L-phenylalanine;L-DOPA;DOPA;L-β-(3,4-Dihydroxyphenyl)-α-alanine;L-(-)-Dopa;β-(3,4-Dihydroxyphenyl)-α-L-alanine;(-)-Dopa;3-(3,4-Dihydroxyphenyl)-L-alanine;β-(3,4-Dihydroxyphenyl)alanine;β-(3,4-Dihydroxyphenyl)-L-alanine;Dihydroxy-L-phenylalanine;Dopar;Levopa;Eldopal;Pardopa;Helfo-dopa;Insulamina;Larodopa;Dopalina;Dopaston;Dopaflex;3,4-Dihydroxyphenylalanine;3,4-Dihydroxyphenyl-L-alanine;L-3-(3,4-Dihydroxyphenyl)alanine;Dopaston SE;L-4,5-Dihydroxyphenylalanine;Dopicar;Dopastone;Dopal;Doparkine;Eurodopa;Dopaidan;Eldopatec;Parda;Eldopar;Dopasol;Laradopa;Weldopa;Doparl;Dopastral;Veldopa;Doprin;Ledopa;Deadopa;Maipedopa;Bendopa;Cidandopa;(2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid;Syndopa;Alphadopa;Dihydroxyphenylalanine;(S)-3,4-Dihydroxyphenylalanine;3-Hydroxytyrosine;Brocadopa;(2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid;Inbrija;23734-74-9;25525-15-9;34241-25-3;72572-99-7;72573-00-3;88250-23-1;90638-38-3
CAS No.:59-92-7
Molecular Formula:C9H11NO4
InChIKeys:InChIKey=WTDRDQBEARUVNC-LURJTMIESA-N
Molecular Weight:197.18800
Exact Mass:197.19
EC Number:200-445-2
UNII:46627O600J
NSC Number:759573|118381
DSSTox ID:DTXSID9023209
NCI Thesaurus Code:C611
Color/Form:Colorless to white crystals or crystalline powder; needles from water
ATC Code:N04BA01|N04BA03|N04BA02|N - Nervous system
HScode:2932999099
Categories:
Characteristics-
PSA:
103.78000
XLogP3:0.75250
Appearance:Solid
Density:1.51 g/cm3
Melting Point:284-286 °C
Boiling Point:448.4±45.0 °C at 760 mmHg
Flash Point:225.0±28.7 °C
Refractive Index:-12 ° (C=5, 1mol/L HCl)
Water Solubility:Slightly soluble in water, dilute hydrochloric acid and formic acid. Insoluble in ethanol.
Storage Conditions:2-8°C
Toxicity:LD50 in mice (mg/kg): 3650 ±327 orally, 1140 ±66 i.p., 450 ±42 i.v., >400 s.c.; in male, female rats (mg/kg): >3000, >3000 orally; 624, 663 i.p.; >1500, >1500 s.c. (Clark)
Specific rotation:Specific optical rotation: -13.1 deg @ 13 °C/D (c= 5.12 in 1 N HCl); max absorption (0.001 N HCl): 220.5 nm (log e= 3.79); 280 nm (log e= 3.42)
Odor:Odorless
Taste:Tasteless
Dissociation Constants:pKa = 2.32
Collision Cross Section:148.7 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|138.21 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|144.27 Ų [M-H]- [CCS Type: DT, Method: stepped-field]|149.4 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|147.5 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|140.6 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|141.2 Ų [M+Na-2H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|145.4 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]|141.6 Ų [M-2H+Na]-
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Skin irritation, Category 2
Specific target organ toxicity â single exposure, Category 3
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
H315 Causes skin irritation
H319 Causes serious eye irritation
H335 May cause respiratory irritation
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P302+P352 IF ON SKIN: Wash with plenty of water/...
P321 Specific treatment (see ... on this label).
P332+P317 If skin irritation occurs: Get medical help.
P362+P364 Take off contaminated clothing and wash it before reuse.
P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P319 Get medical help if you feel unwell.
Storage P403+P233 Store in a well-ventilated place. Keep container tightly closed.
P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Urolithiasis B/Spermine Hydrochloride/ Apigenin/ Theacrine/FAA/OEA/PEA Theobromine/ Squid Ink Powder
-
Location:
Room 1502, Unit 3, Building 2, Nanshan Garden, Jianye 2nd Road, Guodu Subdistrict, Chang'an District, Xi'an City, Shaanxi Province, P.R.China
-
Total Employees:
101-200
-
Year of Establishment:
2017
-
-
Inquiry History7 Inquiries
Country Product Purchase Quantity Date Posted 
Russia
Levodopa 59-92-7 White crystalline powder
180 MT Jun 22, 2026 
Canada
Levodopa
1000 KG Oct 28, 2025 
Indonesia
Levodopa
500 KG Aug 21, 2026 
India
LEVODOPA
1250 KG Jun 22, 2026 
United States
Levodopa
1 KG Oct 27, 2025 
Pakistan
Levodopa
2 G Nov 8, 2023
India
Levodopa
17 MT Apr 28, 2025 Post an enquiry for this product
